Please ensure Javascript is enabled for purposes of website accessibility

Why AcelRx Pharmaceuticals Stock Is Slipping Today

By Keith Speights - Nov 5, 2018 at 12:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nothing to worry about after the biotech received a much-needed FDA approval last week.

What happened

Shares of AcelRx Pharmaceuticals, Inc. (ACRX 5.61%) were down 10.2% as of 11:20 a.m. EST on Monday. The biotech didn't have any new developments. Instead, it appears that some investors took profits off the table following AcelRx's big jump last week after the U.S. Food and Drug Administration (FDA) approved opioid pain drug Dsuvia.

So what

Today's decline should be taken with a grain of salt. Nothing has fundamentally changed for AcelRx since Friday, when the company announced FDA approval for Dsuvia.

Hand holding white pill

Image source: Getty Images.

It's true that the approval attracted a lot of media attention because of worries about the opioid epidemic in the U.S. Such concerns initially helped derail AcelRx's drug last year. Although the biotech presented solid data from a couple of phase 3 clinical studies in its approval application for Dsuvia, the FDA opted against approval because of potential safety concerns.

However, AcelRx cleared the regulatory hurdle this time around -- primarily due to its risk mitigation proposal for Dsuvia in which only qualified healthcare professionals can administer the drug. This approach should significantly reduce the potential for abuse of the opioid drug.

Despite the controversy, the availability of Dsuvia is likely to be applauded by many physicians. Oral and intravenous opioid painkillers that are currently used can be slow to take effect and difficult to appropriately dose and administer. As a single-dose tablet, Dsuvia gives healthcare professionals a convenient way to quickly reduce pain in postoperative patients.

Now what

AcelRx stock could continue to exhibit volatility for a while to come. The company won't launch Dsuvia until the first quarter of 2019. However, cash shouldn't be a problem for AcelRx since it raised $21.7 million in gross proceeds from a stock offering in the third quarter. 

Investors will want to watch for any key updates from AcelRx during its investor day, which is scheduled for Dec. 11, 2018. The biotech plans to seek approval in Europe for Dsuvia. In addition, AcelRx hopes to win FDA approval for its second opioid drug, Zalviso, on a second attempt as well. Although Zalviso is approved in Europe, the FDA gave a thumbs-down in 2014.

AcelRx thinks Dsuvia will generate peak annual sales of $1.1 billion. With the company's market cap currently below $300 million, the stock could still have plenty of room to run even if that target is overly optimistic.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AcelRx Pharmaceuticals, Inc. Stock Quote
AcelRx Pharmaceuticals, Inc.
ACRX
$0.26 (5.61%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.